Flavia Cristofanelli

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

G. Ciliberto, A. Paradiso, F. Baldanti, 2022, Clinical Infectious Diseases.

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

C. Agrati, E. Cimini, C. Castilletti, 2022, Scientific Reports.

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

G. Ciliberto, A. Paradiso, F. Baldanti, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study

C. Agrati, R. Casetti, E. Nicastri, 2022, The Lancet. Infectious diseases.

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

C. Agrati, E. Cimini, C. Castilletti, 2021, Neurology.

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

C. Agrati, E. Cimini, C. Castilletti, 2022, Nature Communications.

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count

C. Agrati, E. Cimini, C. Castilletti, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.